Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST-CarGel
- Development stage
- Unknown
- Lead developer
- Piramal Enterprises
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraarticular
01
Overview
BST-CarGel is a chitosan-based biotherapeutic scaffold designed for the repair of cartilage defects. Originally developed by the Canadian firm BioSyntech and later acquired by Piramal Healthcare (now Piramal Pharma), the product consists of a liquid chitosan-glycerol phosphate solution that is mixed with a patient's autologous blood at the point of care. This mixture is delivered into a cartilage lesion following a microfracture procedure, where it undergoes rapid gelation to stabilize the blood clot. By providing a structural scaffold, BST-CarGel facilitates the recruitment and retention of bone marrow-derived mesenchymal stem cells, promoting the regeneration of hyaline-like cartilage rather than the inferior fibrocartilage typically formed after standard microfracture surgery. The product received CE Mark approval in Europe in 2012 for the treatment of cartilage lesions in the knee.
- Brand names
- BST-CarGel
- Other names
- Chitosan-glycerol phosphate-blood implantChitosan-GP-blood implant
Beyond the preview
Go deeper on BST-CarGel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BST-CarGel.